Takeda, Evozyne expand partnership to develop gene therapies for rare diseases
The expanded collaboration will combine Takeda’s expertise in the rare disease space with Evozyne’s protein engineering capabilities
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Apr 22
The expanded collaboration will combine Takeda’s expertise in the rare disease space with Evozyne’s protein engineering capabilities
05 Apr 22
The US FDA has accepted the company’s supplemental Biologics License Application (sBLA) for tocilizumab and is expected to…
05 Apr 22
AZD8233 is a novel, investigational ASO therapy designed to reduce blood cholesterol levels in patients with hypercholesterolemia (elevated…
04 Apr 22
The Indian pharmaceutical company will obtain the Cidmus trademark in India and is allowed to use the Cidmus…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Apr 22
The FDA approval is based on results from the Phase 3 ZUMA-7 study, evaluating the safety and efficacy…
01 Apr 22
The EC approval was supported by one-year data from the Phase 3 KESTREL and KITE studies, which evaluated…
01 Apr 22
The investment in mAbxience will strengthen the company’s footprint in biopharmaceuticals, and the acquisition of Ivenix will enable…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Mar 22
Triumeq PD is a fixed-dose combination antiretroviral medication containing abacavir, dolutegravir and lamivudine, formulated as a dispersible tablet
31 Mar 22
Neuron23 will use the funding to advance its lead programmes against LRRK2 and TYK2, strengthen its clinical development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Mar 22
The expanded authorisation allows the use of a second booster dose of Pfizer and BioNTech’s Covid-19 vaccine in…